AU Patent

AU2022203809A1 — Azelaic acid esters in the treatment of insulin resistance

Assigned to New Frontier Labs LLC · Expires 2022-06-23 · 4y expired

What this patent protects

A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes dieth…

USPTO Abstract

A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day.

Drugs covered by this patent

Patent Metadata

Patent number: AU2022203809A1
Jurisdiction: AU
Classification: —
Expires: 2022-06-23
Drug substance claim: No
Drug product claim: No
Assignee: New Frontier Labs LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.